Gladstone scientists reprogram skin cells into insulin-producing pancreas cells
A cure for type 1 diabetes has long eluded even the top experts. Not because they do not know what must be done—but because the tools did not exist to do it. But now scientists in the laboratory of Gladstone Institutes’ Investigator Sheng Ding, MD, PhD, harnessing the power of regenerative medicine, have developed a technique in animal models that could replenish the very cells destroyed by the disease. The team’s findings, published online today in the journal Cell Stem Cell, are an important step towards freeing patients from the life-long injections that characterize this devastating disease.
Type 1 diabetes, which usually manifests during childhood, is caused by the destruction of beta-cells (?-cells). ?-cells are a type of cell that normally resides in the pancreas and produces a hormone called insulin. Without insulin, the body’s organs have difficulty absorbing sugars, such as glucose, from the blood. Once a death sentence, the disease can now be managed with regular glucose monitoring and insulin injections. A more permanent solution, however, would be to replace the missing ?-cells. But these cells are hard to come by, so researchers have looked towards stem cell technology as a way to make them.
“The power of regenerative medicine is that it can potentially provide an unlimited source of functional, insulin-producing ?-cells that can then be transplanted into the patient,” said Dr. Ding. “But previous attempts to produce large quantities of healthy ?-cells—and to develop a workable delivery system—have not been entirely successful. So we took a somewhat different approach.”
One of the major challenges to generating large quantities of ?-cells is that these cells have limited regenerative ability; once they mature it’s difficult to make more. So the team decided to go one step backwards in the life cycle of the cell.
The team first collected skin cells, called fibroblasts, from laboratory mice. Then, by treating the fibroblasts with a unique ‘cocktail’ of molecules and reprogramming factors, they transformed the cells into endoderm-like cells. Endoderm cells are a type of cell found in the early embryo, and which eventually mature into the body’s major organs—including the pancreas, the home of ?-cells.
“Using another chemical cocktail, we then transformed these endoderm-like cells into cells that mimicked early pancreas-like cells, which we called PPLC’s,” said Gladstone Postdoctoral Scholar Ke Li, PhD, the paper’s lead author. “Our initial goal was to see whether we could coax these PPLC’s to mature into cells that, like ?-cells, respond to the correct chemical signals and—most importantly—secrete insulin. And our initial experiments, performed in a petri dish, revealed that they did.”
The research team then wanted to see whether the same would occur in live animal models. So they transplanted PPLC’s into mice modified to have hyperglycemia (high glucose levels), a key indicator of diabetes.
“Importantly, just one week post-transplant, the animals’ glucose levels started to decrease, and gradually approached normal levels,” continued Dr. Li. “And when we removed the transplanted cells, we saw an immediate glucose spike, revealing a direct link between the transplantation of the PPLC’s and reduced hyperglycemia.”
But it was when the team tested the mice eight weeks post-transplant that they saw more dramatic changes: the PPLC’s had given rise to functional, insulin-secreting ?-cells.
“These results not only highlight the power of small molecules in cellular reprogramming, and are proof-of-principle that could one day be used as a personalized therapeutic approach in patients,” explained Dr. Ding.
The Latest on: Type 1 Diabetes
via Google News
The Latest on: Type 1 Diabetes
- We’ve all heard of diabetes. But do you know the difference between types 1 and 2?on November 13, 2020 at 12:19 am
Safe to say, most people have heard of diabetes, the disease that affects the way your body regulates blood sugar, or glucose.
- Broadway star from New Orleans to hold virtual fundraiser for Type-1 diabeteson November 12, 2020 at 8:18 pm
A New Orleans Broadway star is using his talents and those of his friends to raise money for Type-1 diabetes research and treatment.
- $14 Million Push for Type 1 Diabetes Breakthroughs: New JDRF Center of Excellence at the University of Michiganon November 12, 2020 at 7:05 am
Michigan Medicine, through its Elizabeth Weiser Caswell Diabetes Institute (EWCDI), and JDRF are collaborating to establish the JDRF Center of Excellence at the University of Michigan. The goal of the ...
- Nearly 1 in 5 COVID-19 deaths in the African region linked to diabeteson November 12, 2020 at 5:51 am
The World Health Organization (WHO) finds that 18.3% of COVID-19 deaths in the African region are among people with diabetes, one of the conditions that global studies have found to increase the risk ...
- More than my diagnosis: Native Nevadan hopes to inspire others with type 1 diabeteson November 11, 2020 at 6:07 pm
... diabetes at a younger age because i don’t remember life without it,” said diabetes advocate Wes Fullmer. He was only five years old when he was diagnosed with type 1 diabetes, a condition in which ...
- Student Shares Her Battle With Type 1 Diabeteson November 9, 2020 at 4:15 pm
When Sydney Smith woke up this morning, her mind immediately went to her blood sugar. She grabbed her insulin pump and looked at the growing screen, the number appearing forewarning whether she would ...
- Bridget Gamble Teaches Kids About Type 1 Diabetes in “Connie-Sue, Where are You?”on November 6, 2020 at 1:18 pm
Passionate teacher and author, Bridget Gamble, releases a new interactive book titled “Connie-Sue, Where are You?” where she aims to teach children about Type 1 Diabetes in a creative way Bridget ...
- CymaBay Announces Study to Evaluate the Potential for GPR119 Agonists to Prevent Hypoglycemia in Type 1 Diabeteson November 5, 2020 at 6:09 am
The AdventHealth Translational Research Institute (TRI) in Orlando, FL to lead the study, funded by the Helmsley Charitable Trust, evaluating MBX-2982, a GPR119 agonist, for its ability to increase ...
- CymaBay Announces Study to Evaluate the Potential for GPR119 Agonists to Prevent Hypoglycemia in Type 1 Diabeteson November 5, 2020 at 12:00 am
The trial is funded by a nearly $1.2 million grant from The Leona M ... oral GPR119 agonist that has previously been studied in type 2 diabetes. It has a favorable profile in non-clinical ...
- Joplin resident overcomes type 1 diabetes to complete marathonon November 1, 2020 at 8:31 am
Doak is a member of the "10% Club," which is the percentage of Americans with Type 1 diabetes, the most severe form of the disease. It occurs when the body’s immune system mistakenly identifies ...
via Bing News